EDEN PRAIRIE, MN, United States, via eTeligis Inc., 05/27/2014 - - PetVivo Holdings, Inc. (OTCQB: PETV), an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics today announced that an interview with John Lai, CEO of the company from the Growth Capital Expo is now available at:
Click here: SNNLive - https://www.youtube.com/watch?v=BjZ7frYOlIk
The interview was conducted by Sheldon (Shelly) Kraft and recorded by SNN Live on May 1, 2014, at the Growth Capital Expo in Las Vegas. Shelly Kraft is the founder and CEO of SNN Inc. and publisher of Micro-Cap Review.
In the interview Mr. Lai mentioned that he looked at the marketplace and realized that there was a need to bring human therapeutics and medical devices to the companion animal market (for simplicity referred to as drugs in interview). Many companies are advancing products for human use through the FDA review and clinical trial process and we recognize that advancing veterinary therapeutics and medical devices through the FDA would be much quicker and significantly less expensive. "There is a great opportunity to bring those products to market thereby enhancing the quality of life for companion animals." Our first product Kush™ is a medical device for the treatment of osteoarthritis, which is licensed from Gel-Del Technologies and already meets FDA guidelines as a medical device. Kush is ready for veterinary use with a commercial launch scheduled for Q4 2014.
For more information visit: www.petvivo.com
About PetVivo, Inc.:
PetVivo, Inc. is a wholly owned subsidiary of PetVivo Holdings, Inc. (OTCQB: PETV) based in Minneapolis, Minnesota. PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and other therapeutics for pets.
PetVivo, Inc. believes that it can leverage the investments in the human bio-materials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo's strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
About SNN & Sheldon Kraft:
SNN Incorporated is a global multimedia financial news and publishing company for market awareness and investor visibility of public and private micro-cap companies. SNN publishes the Micro-Cap Review print & web magazine, www.stocknewsnow.com financial portal, the Ask Mr. WallStreet Newsletter, www.SNNwire.com & the Patent Pending, SNN Video Press Release, VPR™. SNN owns and operates the SNNLiveTV™ show & the SNN StockUmentary™ TV show.
Sheldon (Shelly) Kraft, founder and CEO of SNN Inc, publisher of Micro-Cap Review has more than 30 years experience in virtually all areas of Micro-Cap financing. He was an investment banker on Wall Street and President of Emmanuel & Co. specializing in funding micro-cap companies. He is an author, speaker, expert and founded SNN in 1998 which is a global, multimedia, financial news and publishing company. He serves as a member of the International Stock Exchange Executives Emeriti, Inc.
The fore-going material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
John Lai
Chief Executive Officer
PetVivo Holdings, Inc.
Email: info@petvivo.com
Phone: 612-296-7305
SOURCE: PetVivo Holdings, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
PETV_5-27-14_LST_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment